Evans et al. analyzed the PD‐L1 expression among 10 005 patients with NSCLC in the UK and found that classical EGFR mutations were associated with lower rates of PD‐L1 expression, and nonclassical EGFR mutations were associated with higher rates.60 Here, EGFR is linked to non-small cell lung carcinoma.